Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03673501




Registration number
NCT03673501
Ethics application status
Date submitted
13/09/2018
Date registered
17/09/2018
Date last updated
2/01/2024

Titles & IDs
Public title
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Scientific title
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
Secondary ID [1] 0 0
DCC-2618-03-002
Universal Trial Number (UTN)
Trial acronym
INTRIGUE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastrointestinal Stromal Tumors 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach
Cancer 0 0 0 0
Bowel - Small bowel (duodenum and ileum)
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ripretinib
Treatment: Drugs - Sunitinib

Experimental: Ripretinib - Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles

Active Comparator: Sunitinib - Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.


Treatment: Drugs: Ripretinib
Oral KIT/PDGFRA kinase inhibitor

Treatment: Drugs: Sunitinib
Oral receptor tyrosine kinase (RTK) inhibitor
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population
Timepoint [1] 0 0
From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
Primary outcome [2] 0 0
Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population
Timepoint [2] 0 0
From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
Secondary outcome [1] 0 0
Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population
Timepoint [1] 0 0
From confirmed CR or PR to disease progression (up to 1.74 years)
Secondary outcome [2] 0 0
Objective Response Rate (ORR) in the All Patient (AP) Intent to Treat (ITT) Population
Timepoint [2] 0 0
From confirmed CR or PR to disease progression (up to 1.74 years)
Secondary outcome [3] 0 0
Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population
Timepoint [3] 0 0
From date of randomization until death due to any cause (up to 3.33 years)
Secondary outcome [4] 0 0
Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population
Timepoint [4] 0 0
From date of randomization until death due to any cause (up to 3.33 years)

Eligibility
Key inclusion criteria
1. Patients = 18 years of age at the time of informed consent.

2. Histologic diagnosis of GIST and must be able to provide an archival tumor tissue
sample, otherwise, a fresh biopsy is required.

3. Molecular pathology report must be available. If molecular pathology report is not
available or insufficient, an archival tumor tissue sample or fresh biopsy is required
for mutation status confirmation by the central laboratory prior to randomization.

4. Patients must have progressed on imatinib or have documented intolerance to imatinib.

5. Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of = 2 at screening.

6. Female patients of childbearing potential must have a negative serum beta-human
chorionic gonadotropin (ß-hCG) pregnancy test at screening and negative pregnancy test
at Cycle 1 Day 1 prior to the first dose of study drug.

7. Patients of reproductive potential must agree to follow the contraception requirements
outlined in the study protocol.

8. Patients must have at least 1 measurable lesion according to Modified Response
Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1 (non nodal lesions must be =
1.0 cm in the long axis or = double the slice thickness in the long axis) within 21
days prior to the first dose of study drug.

9. Adequate organ function and bone marrow reserve as indicated by the central laboratory
assessments performed at screening.

10. Resolution of all toxicities from prior therapy to = Grade 1 (or patient baseline)
within 1 week prior to the first dose of study drug (excluding alopecia and = Grade 3
clinically asymptomatic lipase, amylase, and creatine phosphokinase laboratory
abnormalities).

11. The patient is capable of understanding and complying with the protocol and the
patient has signed the informed consent document. Signed informed consent form (ICF)
must be obtained before any study-specific procedures are performed and the patient
must agree to not participate in any other interventional clinical trial while on
treatment in this clinical trial. Participation in a noninterventional study
(including observational studies) is permitted.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Treatment with any other line of therapy in addition to imatinib for advanced GIST.
Imatinib-containing combination therapy in the first-line setting is not allowed.

2. Patients with a prior or concurrent malignancy whose natural history or treatment have
the potential to interfere with the safety or efficacy assessment of this clinical
trial are not eligible.

3. Patient has known active central nervous system metastases.

4. New York Heart Association class II-IV heart disease, myocardial infarction within 6
months of cycle 1 day 1, active ischemia or any other uncontrolled cardiac condition
such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy,
uncontrolled hypertension or congestive heart failure.

5. Left ventricular ejection fraction (LVEF) < 50% at screening.

6. Arterial thrombotic or embolic events such as cerebrovascular accident (including
ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.

7. Venous thrombotic events (e.g. deep vein thrombosis) or pulmonary arterial events
(e.g. pulmonary embolism) within 1 month before the first dose of study drug. Patients
on stable anticoagulation therapy for at least one month are eligible.

8. 12-lead ECG demonstrating QT interval corrected (QTc) by Fridericia's formula > 450 ms
in males or > 470 ms in females at screening or history of long QTc syndrome

9. Use of known substrates or inhibitors of breast cancer resistance protein (BCRP)
transporters within 14 days or 5 x the half-life (whichever is longer) prior to the
first dose of study drug.

10. Major surgeries (e.g. abdominal laparotomy) within 4 weeks of the first dose of study
drug. All major surgical wounds must be healed and free of infection or dehiscence
before the first dose of study drug.

11. Any other clinically significant comorbidities.

12. Known human immunodeficiency virus or hepatitis C infection only if the patient is
taking medications that are excluded per protocol, active hepatitis B, or active
hepatitis C infection.

13. If female, the patient is pregnant or lactating.

14. Known allergy or hypersensitivity to any component of the study drug.

15. Gastrointestinal abnormalities including but not limited to:

- inability to take oral medication

- malabsorption syndromes

- requirement for intravenous (IV) alimentation

16. Any active bleeding excluding hemorrhoidal or gum bleeding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/02/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2024
Actual
Sample size
Target
Accrual to date
Final
453
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Border Medical Oncology Research Unit - Albury
Recruitment hospital [2] 0 0
Prince of Wales Hospital - Randwick
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Ashford Cancer Centre Research - Kurralta Park
Recruitment hospital [5] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [6] 0 0
Princess Alexandara Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
- Albury
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
- Woolloongabba
Recruitment postcode(s) [4] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [5] 0 0
- Kurralta Park
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oklahoma
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Argentina
State/province [29] 0 0
Cordoba
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Belgium
State/province [31] 0 0
Bruxelles
Country [32] 0 0
Belgium
State/province [32] 0 0
Leuven
Country [33] 0 0
Canada
State/province [33] 0 0
Alberta
Country [34] 0 0
Canada
State/province [34] 0 0
Manitoba
Country [35] 0 0
Canada
State/province [35] 0 0
Ontario
Country [36] 0 0
Canada
State/province [36] 0 0
Québec
Country [37] 0 0
Chile
State/province [37] 0 0
Santiago
Country [38] 0 0
Czechia
State/province [38] 0 0
Prague
Country [39] 0 0
France
State/province [39] 0 0
Bordeaux
Country [40] 0 0
France
State/province [40] 0 0
Dijon
Country [41] 0 0
France
State/province [41] 0 0
Lille Cedex
Country [42] 0 0
France
State/province [42] 0 0
Lyon
Country [43] 0 0
France
State/province [43] 0 0
Marseille
Country [44] 0 0
France
State/province [44] 0 0
Paris
Country [45] 0 0
France
State/province [45] 0 0
Poitiers
Country [46] 0 0
France
State/province [46] 0 0
Saint Herblain
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Dresden
Country [49] 0 0
Germany
State/province [49] 0 0
Essen
Country [50] 0 0
Hungary
State/province [50] 0 0
Budapest
Country [51] 0 0
Hungary
State/province [51] 0 0
Debrecen
Country [52] 0 0
Israel
State/province [52] 0 0
Be'er Ya'akov
Country [53] 0 0
Israel
State/province [53] 0 0
Petah Tikva
Country [54] 0 0
Israel
State/province [54] 0 0
Tel Aviv
Country [55] 0 0
Italy
State/province [55] 0 0
Bologna
Country [56] 0 0
Italy
State/province [56] 0 0
Meldola
Country [57] 0 0
Italy
State/province [57] 0 0
Milan
Country [58] 0 0
Italy
State/province [58] 0 0
Padova
Country [59] 0 0
Italy
State/province [59] 0 0
Palermo
Country [60] 0 0
Italy
State/province [60] 0 0
Rome
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Seoul
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Suwon
Country [63] 0 0
Netherlands
State/province [63] 0 0
Amsterdam
Country [64] 0 0
Netherlands
State/province [64] 0 0
Groningen
Country [65] 0 0
Netherlands
State/province [65] 0 0
Leiden
Country [66] 0 0
Norway
State/province [66] 0 0
Oslo
Country [67] 0 0
Poland
State/province [67] 0 0
Warsaw
Country [68] 0 0
Singapore
State/province [68] 0 0
Singapore
Country [69] 0 0
Spain
State/province [69] 0 0
Barcelona
Country [70] 0 0
Spain
State/province [70] 0 0
Bilbao
Country [71] 0 0
Spain
State/province [71] 0 0
Madrid
Country [72] 0 0
Spain
State/province [72] 0 0
Malaga
Country [73] 0 0
Spain
State/province [73] 0 0
Sevilla
Country [74] 0 0
Spain
State/province [74] 0 0
Valencia
Country [75] 0 0
Spain
State/province [75] 0 0
Vigo
Country [76] 0 0
Sweden
State/province [76] 0 0
Solna
Country [77] 0 0
Switzerland
State/province [77] 0 0
Lausanne
Country [78] 0 0
Switzerland
State/province [78] 0 0
Zurich
Country [79] 0 0
Taiwan
State/province [79] 0 0
Taoyuan County
Country [80] 0 0
Taiwan
State/province [80] 0 0
Kaohsiung
Country [81] 0 0
Taiwan
State/province [81] 0 0
Taichung
Country [82] 0 0
Taiwan
State/province [82] 0 0
Tainan
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taipei
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Glasgow
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Leeds
Country [86] 0 0
United Kingdom
State/province [86] 0 0
London
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Deciphera Pharmaceuticals LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a 2-arm, randomized, open-label, international, multicenter study comparing the
efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to
first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized
in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or
sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
Trial website
https://clinicaltrials.gov/ct2/show/NCT03673501
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03673501